Focus:
Deal News
-
18 June 2019
Pfizer to acquire US company Array BioPharma for $11.4bn
Pfizer has signed a definitive merger agreement to acquire US-based, commercial-stage biopharmaceutical company Array BioPharma.
-
17 June 2019
Theravance and Mylan expand agreement for nebulised revefenacin
Theravance Biopharma Ireland and Mylan have expanded their existing development and commercialisation agreement for nebulised revefenacin.
-
17 June 2019
Upsher-Smith to buy migraine drugs from Dr Reddy’s
Upsher-Smith Laboratories has signed a definitive asset purchase agreement to acquire neurology products from Dr Reddy’s Laboratories.
-
14 June 2019
Egis Pharmaceuticals to launch Mundipharma’s Pelmeg in CEE markets
Mundipharma has signed an exclusive distribution agreement that will see Egis Pharmaceuticals introduce its Pelmeg drug in four Central and Eastern Europe (CEE) markets.
-
14 June 2019
GSK and University of California team up on CRISPR research
UK-based GlaxoSmithKline (GSK) has partnered with the University of California to carry out genomic research for drug discovery applications.
-
14 June 2019
Synlogic and Ginkgo Bioworks to develop biotic drugs
Synlogic has entered a platform collaboration with biotech company Ginkgo Bioworks to support its synthetic bionic medicines pipeline.
-
13 June 2019
Genmab and Janssen Biotech to develop CD38 antibody
Genmab has signed a global licence and option agreement with Janssen Biotech for the development and commercialisation of a human CD38 monoclonal antibody (mAb).
-
13 June 2019
Sobi to acquire emapalumab drug from Novimmune
Swedish Orphan Biovitrum (Sobi) has agreed to buy a newly established firm from Novimmune for a consideration of SEK4,897m ($517.9m).
-
12 June 2019
Deciphera licenses cancer drug ripretinib to Zai Lab in China
US-based Deciphera Pharmaceuticals has signed an exclusive licence agreement with biopharmaceutical company Zai Lab to develop and commercialise cancer therapeutic ripretinib in Greater China.
-
12 June 2019
Boehringer expands PROTAC drugs partnership with Dundee University
Boehringer Ingelheim has extended a collaboration with the University of Dundee in Scotland for the development of proteolysis targeting chimera (PROTAC) based drugs to treat cancer.
Close
Close
Close
Go Top
